208 related articles for article (PubMed ID: 8722344)
21. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease.
Bolinger AM; Zangwill AB; Slattery JT; Glidden D; DeSantes K; Heyn L; Risler LJ; Bostrom B; Cowan MJ
Bone Marrow Transplant; 2000 May; 25(9):925-30. PubMed ID: 10800058
[TBL] [Abstract][Full Text] [Related]
22. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
23. An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.
Takamatsu Y; Ogata K; Yamauchi K; Hara S; Kamimura T; Hayashi S; Suzumiya J; Tamura K
Jpn J Clin Oncol; 2005 Jul; 35(7):400-3. PubMed ID: 15976066
[TBL] [Abstract][Full Text] [Related]
24. [Effect of BU and CY versus TBI and CY as conditioning regimens on the efficacy of haploidentical stem cell transplantation in patients with hematologic malignancy].
Shao Q; Han D; Liu D; Zheng X; Dong L; Wang Z; Ding L; Yan H; Wang H; Duan L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):505-10. PubMed ID: 24985173
[TBL] [Abstract][Full Text] [Related]
25. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia.
Dusenbery KE; Daniels KA; McClure JS; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Kersey JH; Woods WG
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):119-28. PubMed ID: 7995742
[TBL] [Abstract][Full Text] [Related]
26. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
27. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
[TBL] [Abstract][Full Text] [Related]
28. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
[TBL] [Abstract][Full Text] [Related]
29. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
Baker KS; Bostrom B; DeFor T; Ramsay NK; Woods WG; Blazar BR
Bone Marrow Transplant; 2000 Sep; 26(6):607-14. PubMed ID: 11041565
[TBL] [Abstract][Full Text] [Related]
30. Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience.
Dusenbery KE; Steinbuch M; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Litz C; Kersey JH; Woods WG
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):335-43. PubMed ID: 8892457
[TBL] [Abstract][Full Text] [Related]
31. Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine.
de Castro FA; Simões BP; Godoy AL; Bertagnoli Trigo FM; Coelho EB; Lanchote VL
J Clin Pharmacol; 2016 Dec; 56(12):1555-1562. PubMed ID: 27130252
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies.
Lynch MH; Petersen FB; Appelbaum FR; Bensinger WI; Clift RA; Storb R; Sanders JE; Hansen JA; Buckner CD
Bone Marrow Transplant; 1995 Jan; 15(1):59-64. PubMed ID: 7742756
[TBL] [Abstract][Full Text] [Related]
33. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy.
Kuwatsuka Y; Kohno A; Terakura S; Saito S; Shimada K; Yasuda T; Inamoto Y; Miyamura K; Sawa M; Murata M; Karasuno T; Taniguchi S; Nagafuji K; Atsuta Y; Suzuki R; Fukumoto M; Naoe T; Morishita Y;
Cancer Sci; 2012 Sep; 103(9):1688-94. PubMed ID: 22631696
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
Mannis GN; Andreadis C; Logan AC; Damon LE; Benet LZ; Ai WZ; Gaensler KM; Kaplan LD; Koplowicz YB; Linker CA; Olin RL; Sayre PH; Smith CC; Sudhindra A; Venstrom JM; Wolf JL; Martin TG
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):377-83. PubMed ID: 25776193
[TBL] [Abstract][Full Text] [Related]
36. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia.
Davies SM; Ramsay NK; Klein JP; Weisdorf DJ; Bolwell B; Cahn JY; Camitta BM; Gale RP; Giralt S; Heilmann C; Henslee-Downey PJ; Herzig RH; Hutchinson R; Keating A; Lazarus HM; Milone GA; Neudorf S; Perez WS; Powles RL; Prentice HG; Schiller G; Socié G; Vowels M; Wiley J; Yeager A; Horowitz MM
J Clin Oncol; 2000 Jan; 18(2):340-7. PubMed ID: 10637248
[TBL] [Abstract][Full Text] [Related]
37. Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis.
Shi-Xia X; Xian-Hua T; Hai-Qin X; Bo F; Xiang-Feng T
Leuk Lymphoma; 2010 Jan; 51(1):50-60. PubMed ID: 20055658
[TBL] [Abstract][Full Text] [Related]
38. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Martino R; Pérez-Simón JA; Moreno E; Queraltó JM; Caballero D; Mateos M; Sureda A; Cañizo C; Brunet S; Briones J; Vazquez L; Clopés A; San Miguel JF; Sierra J
Biol Blood Marrow Transplant; 2005 Jun; 11(6):437-47. PubMed ID: 15931632
[TBL] [Abstract][Full Text] [Related]
39. Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.
Wong JY; Forman S; Somlo G; Rosenthal J; Liu A; Schultheiss T; Radany E; Palmer J; Stein A
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):148-56. PubMed ID: 22592050
[TBL] [Abstract][Full Text] [Related]
40. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
